Advocacy intelligence hub — real-time data for patient organizations
Peking Union Medical College Hospital — NA
Ultragenyx Pharmaceutical Inc
Crysvita: FDA approved
Crysvita (burosumab-twza) is indicated for the treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized.
Zometa, Zabel: FDA approved
Treatment of hypercalcemia of malignancy.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Zometa, Zabel
Novartis Pharmaceuticals Corp.
Patient Assistance Programs1
Crysvita
Kyowa Kirin, Inc.
Matthew Drake, MD
Mayo Clinic
Stephen M Broski, MD, M.D
Mayo Clinic
📍 ROCHESTER, MN
Shyang-Rong Shih, PhD
National Taiwan University Hospital
Boehringer Ingelheim
The Institute for Liver Health II DBA Arizona Clinical Trials
📍 Peoria, Arizona
Naveen H Chandrasekhar
Mazumdar Shaw Cancer Centre
Vishal Yadav
Mazumdar Shaw Cancer Centre